- Nearly 5000 pregnant women are infected with COVID-19
- Powell dies due to COVID-19 Also suffered Multiple Myeloma
- Hundreds millions of Nike shoes could not be delivered due to COVID-19
- How long is the protection period of COVID-19 vaccines?
- What are the differences between the current COVID-19 vaccines?
- Will EMT become the new target for the treatment of colorectal cancer?
AMGEN: KRAS Target Drugs Inhibiting 81% of Non-Small Cell Lung Cancer Tumor Growth
AMGEN: KRAS Target Drugs Inhibiting 81% of Non-Small Cell Lung Cancer Tumor Growth. Amgen Announces Clinical Trial Data of KRAS Target Drugs, Inhibiting 81% of Non-Small Cell Lung Cancer Tumor Growth.
The launch of RAS targeted therapy AMG510 will be an exciting time, renewing our hope for the successful treatment of RAS mutant cancers.
Pay attention to scientific research bacteria ↑↑↑ More original scientific research dry goods are waiting for you!
Amgen is currently seeking to target its KRAS G12C gene mutation Sotorasib as a second-line treatment for non-small cell lung cancer (NSCLC) in the United States, the United Kingdom, the European Union, Canada, Australia and Brazil.
With the gradual submission of applications for the first KRAS inhibitor drug in history to drug regulatory agencies in many countries and regions around the world, Amgen recently announced that it has targeted non-small cell lung cancer (NSCLC). ) The patient’s largest treatment data.
At the World Lung Cancer Conference on Friday in the US Eastern Time, Amgen will announce the detailed results of Sotorasib’s Phase 2 clinical trial on 126 non-small cell lung cancer (NSCLC) patients. These 126 announced Sotorasib versus 126 Non-small cell lung cancer (NSCLC) patients, their tumors all carry the KRAS G12C gene mutation. Although they have tried as many as 3 treatment options, their cancer has become more serious, and then they received Sotorasib treatment.
Sotorasib drug inhibited tumor growth in 81% of patients, reduced tumor size in 37% of patients, and even more gratifyingly, all signs of cancer disappeared in three cancer patients (2%). Sotorasib prevented tumor growth for a median of 6.8 months, and the median patient response to treatment was 10 months.
In addition, Sotorasib is relatively safe, with about two-thirds of patients reporting side effects, but most of them are mild to moderate. The most common side effects were diarrhea (31%), nausea (19%), elevated liver enzymes (15%), and no deaths related to drug therapy occurred, but 7% of patients withdrew from the study due to side effects. Researchers are Research how to further control side effects, but researchers also said that compared with docetaxel and other therapies, Sotorasib has a good safety prospect.
RAS (KRAS, NRAS and HRAS) are the most common mutant gene families in cancer. KRAS mutations are an important driver of the three deadliest cancers known-lung cancer, colorectal cancer and pancreatic cancer.
For more than 30 years, the development of effective therapies to inhibit RAS-driven tumorigenesis has been stagnant, so RAS was once considered a “non-drugable target.”
However, at the ASCO Conference in 2019, Amgen announced its research and development of the inhibitor AMG 510 (Sotorasib) for non-small cell lung cancer with mutations in the KRAS G12C gene. It has significant effects on 10 non-small cells with mutations in the KRAS G12C gene. The disease control rate of lung cancer (NSCLC) is close to 90%, and the effective rate is 50%. Once the data was released, it caused a worldwide sensation. The view that RAS is not medicine is successfully shaken.
On December 9, 2020, Amgen announced that the U.S. FDA has granted its research KRAS G12C inhibitor AMG 510 (Sotorasib) breakthrough therapy designation and adopts real-time review (RTOR) to speed up the review process for local treatment Advanced or metastatic non-small cell lung cancer (NSCLC) patients with KRAS G12C mutation.
On December 16, 2020, Amgen announced that it has submitted a marketing application for AMG 510 (Sotorasib) to the FDA for the treatment of advanced metastatic non-small cell lung cancer (NSCLC) with KRAS G12C mutation.
RAS mutations and cancer
RAS mutations are genetic drivers of many cancer types, including colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), lung adenocarcinoma (LUAD, a subtype of non-small cell lung cancer), as well as melanoma and certain blood systems cancer.
Although these tumor types are driven by RAS mutations, the isoforms (KRAS, NRAS, HRAS), codons, and frequency of RAS mutations vary by tissue type.
Specifically, 32% of lung adenocarcinoma (LUAD), 86% of pancreatic ductal adenocarcinoma (PDAC), and 41% of colorectal cancer (CRC) are driven by KRAS mutations, which mainly occur in code 12 Sub-office.
29% of melanomas are driven by NRAS mutations. Unlike KRAS, these mutations occur at codon 61.
In contrast, HRAS mutations occur less frequently than mutations in KRAS or NRAS. 5% of head and neck squamous cell carcinomas (HNSCC) and 6% of bladder cancers are driven by HRAS mutations, which occur in the first At codon 12 or 61.
Clinical development of RAS mutant tumor inhibitors
In general, the launch of the RAS targeted therapy AMG510 will be an exciting time, renewing our hope for the successful treatment of RAS mutant cancers.
(source:chinanet, reference only)